Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017–2022
| dc.contributor.author | Dahl, Victor Naestholt | |
| dc.contributor.author | Butova, Tetiana | |
| dc.contributor.author | Rosenthal, Alex | |
| dc.contributor.author | Grinev, Alina | |
| dc.contributor.author | Gabrielian, Andrei | |
| dc.contributor.author | Vashakidze, Sergo | |
| dc.contributor.author | Shubladze, Natalia | |
| dc.contributor.author | Toxanbayeva, Bekzat | |
| dc.contributor.author | Chingissova, Lyailya | |
| dc.contributor.author | Crudu, Valeriu | |
| dc.contributor.author | Chesov, Dumitru | |
| dc.contributor.author | Kalmambetova, Gulmira | |
| dc.contributor.author | Saparova, Gulbarchyn | |
| dc.contributor.author | Wejse, Christian Morberg | |
| dc.contributor.author | Butov, Dmytro | |
| dc.date.accessioned | 2024-11-06T17:46:52Z | |
| dc.date.issued | 2024-04-04 | |
| dc.description.abstract | In 2021, the World Health Organization recommended new extensively drug-resistant (XDR) and pre-XDR tuberculosis (TB) definitions. In a recent cohort of TB patients in Eastern Europe, we show that XDR TB as currently defined is associated with exceptionally poor treatment outcomes, considerably worse than for the former definition (31% vs. 54% treatment success). | |
| dc.identifier.citation | Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017–2022 / V. N. Dahl, T. Butova, A. Rosenthal [et al.] // Emerging Infectious Diseases. ─ 2024. ─ № 30 (4). ─ P. 831─833. | |
| dc.identifier.issn | 10806040 | |
| dc.identifier.issn | 10806059 | |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/34622 | |
| dc.language.iso | en_US | |
| dc.publisher | Centers for Disease Control and Prevention (CDC) | |
| dc.subject | drug-resistant tuberculosis | |
| dc.subject | 2024а | |
| dc.title | Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017–2022 | |
| dc.type | Article |